Conceptus Inc.

Conceptus Inc. was an American medical-products manufacturer and developer founded in 1992 and headquartered in Mountain View, California. The company built its early expertise around micro-catheter and guidewire systems designed to help physicians reach and navigate the fallopian tubes without making an incision. These technologies were initially developed for applications involving the diagnosis and treatment of infertility. In 1998, Conceptus concentrated its research and clinical-development efforts on Essure, a non-incisional alternative to conventional tubal ligation. Tubal ligation generally involves cutting, clipping, or burning the fallopian tubes. Essure was designed around placement through the natural reproductive tract, using catheter-based delivery to position inserts in the fallopian tubes. The intended result was permanent contraception without abdominal surgery. Following clinical testing, Conceptus began commercial marketing of Essure in Australia, Singapore, Europe, and Canada. The product subsequently received approval from the United States Food and Drug Administration in 2002, allowing it to be marketed in the United States. Essure became the company's principal commercial offering and defined Conceptus's identity within the medical-device sector. Conceptus remained an independent publicly traded company until Bayer AG agreed in April 2013 to acquire it for $31 per share in cash. The offer represented a reported 20 percent premium to Conceptus's market price and valued the transaction at approximately $1.1 billion. The acquisition closed on June 5, 2013, after which Conceptus became a wholly owned subsidiary of Bayer, a German healthcare and life-sciences group. The company's history reflects a medical-device business organized around minimally invasive access technology and a flagship reproductive-health product. Its principal strategic contribution to Bayer was the Essure franchise and the underlying catheter-based development expertise. Publicly available reference material identifies Conceptus primarily through its formation, Essure development and international commercialization, regulatory approval in the United States, and acquisition by Bayer. Detailed information about post-acquisition corporate operations, current branding, executive leadership, and any later product portfolio is not established in the supplied sources.

Conceptus Inc. was established in 1992 in the United States and operated from Mountain View, California. Its initial technical work centered on micro-catheter and guidewire systems intended to provide physicians with non-incisional access to the fallopian tubes. The company developed these technologies in connection with infertility diagnosis and treatment, giving it an early specialization in catheter-based reproductive medicine. In 1998, Conceptus redirected its principal development effort toward Essure. The product was conceived as a non-incisional alternative to tubal ligation, a permanent contraceptive procedure traditionally involving the cutting, clipping, or burning of the fallopian tubes. Essure used a catheter-delivery approach rather than abdominal surgery. Conceptus undertook clinical testing to evaluate the system and subsequently commercialized it in Australia, Singapore, Europe, and Canada. Essure received approval from the United States Food and Drug Administration in 2002. The authorization enabled commercial use in the United States and made Essure the central product associated with Conceptus. The company's identity consequently became closely linked to permanent contraception, minimally invasive gynecological procedures, and device systems for fallopian-tube access. Conceptus was acquired by Bayer AG in 2013. On April 29 of that year, Bayer made a cash offer of $31 per share, reportedly representing a 20 percent premium over Conceptus's market price and an overall transaction value of about $1.1 billion. The deal closed on June 5, 2013. From that point, Conceptus operated as a wholly owned subsidiary of Bayer, a German healthcare and life-sciences company. The supplied reference material does not provide a detailed account of Conceptus's post-acquisition structure, leadership, additional products, or later corporate status. Its documented historical significance rests on the development and commercialization of Essure and on Bayer's acquisition of the company.

• 2013

  Bayer acquires Conceptus

  [1]Conceptus Inc.en.wikipedia.org

  Bayer AG agrees to acquire Conceptus for $31 per share in cash, valuing the transaction at approximately $1.1 billion; the deal closes on June 5.

• 2002

  Essure is approved in the United States

  [1]Conceptus Inc.en.wikipedia.org

  The United States Food and Drug Administration approves Essure for use in the United States.

• 1998

  Development focus shifts to Essure

  [1]Conceptus Inc.en.wikipedia.org

  Conceptus focuses its design, development, and clinical-testing program on Essure, a non-incisional alternative to tubal ligation.

• 1992

  Conceptus is founded

  [1]Conceptus Inc.en.wikipedia.org

  Conceptus Inc. is established as an American medical-products company and later operates from Mountain View, California.

Conceptus positioned itself as a medical-device innovator focused on catheter-based, non-incisional access to the fallopian tubes and minimally invasive reproductive-health procedures.

• Permanent contraception medical device · 2002

  Essure

  Essure was Conceptus's principal product and was developed as a non-incisional alternative to tubal ligation. The system used catheter-based delivery to access the fallopian tubes, avoiding the cutting, clipping, and burning associated with conventional surgical sterilization. Conceptus conducted clinical testing before marketing Essure in Australia, Singapore, Europe, and Canada, followed by United States FDA approval in 2002.

• Medical access devices

  Micro-catheter and guidewire systems

  Conceptus began by developing micro-catheter and guidewire systems that enabled physicians to reach and navigate the fallopian tubes without an incision. The technology was initially associated with infertility diagnosis and treatment and later formed part of the technical foundation for the company's Essure development program.

• 2013

  Accept Bayer's acquisition offerM&A

  Background

  Bayer AG offered to purchase Conceptus in an all-cash transaction at a reported premium to the company's market price.

  Action taken

  Conceptus was acquired by Bayer for $31 per share; the transaction closed on June 5, 2013.

  Aftermath

  Conceptus became a wholly owned subsidiary of Bayer AG.

  Transaction value. $1.1 billion (2013 acquisition)

  Source

• 2002

  Commercialize Essure in the United StatesProduct launch

  Background

  Essure had undergone clinical testing and had been marketed in Australia, Singapore, Europe, and Canada.

  Action taken

  Following United States Food and Drug Administration approval, Conceptus made Essure available for use in the United States.

  Aftermath

  The United States became one of the documented markets for Conceptus's flagship reproductive-health device.

  Source

• 1998

  Concentrate development on EssureStrategy

  Background

  Conceptus had developed catheter and guidewire technologies for fallopian-tube access, initially in connection with infertility applications.

  Action taken

  The company shifted its design, development, and clinical-testing focus toward Essure as a non-incisional alternative to tubal ligation.

  Aftermath

  Essure became Conceptus's principal commercial product and the basis for its later international expansion and United States regulatory approval.

  Source

1. 1Conceptus Inc.en.wikipedia.org